Leap Therapeutics to Present at 22nd Annual BIO CEO & Investor Conference

On February 4, 2020 Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported that Douglas E. Onsi, Chief Financial Officer, will present a corporate overview at the 22nd Annual BIO CEO & Investor Conference, being held in New York City on February 10-11, 2020 (Press release, Leap Therapeutics, FEB 4, 2020, View Source;investor-conference-300998023.html [SID1234553859]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leap Presentation Details:

22nd Annual BIO CEO & Investor Conference
Date: Tuesday, February 11, 2020
Time: 11:15 a.m. Eastern Time

The presentation will be webcast live and may be accessed on the Investors page of the company’s website at View Source, where a replay of the event will also be available for a limited time.

Gilead Sciences Announces 8 Percent Increase In First Quarter 2020 Dividend

On February 4, 2020 Gilead Sciences, Inc. (Nasdaq: GILD) reported that the company’s Board of Directors has declared an increase of 8% in the company’s quarterly cash dividend, beginning in the first quarter of 2020 (Press release, Gilead Sciences, FEB 4, 2020, View Source [SID1234553893]). The increase will result in a quarterly dividend of $0.68 per share of common stock. The dividend is payable on March 30, 2020, to stockholders of record at the close of business on March 13, 2020. Future dividends will be subject to Board approval.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


NAVROGEN AND LEVENA ANNOUNCE COLLABORATION TO DEVELOP ANTIBODY DRUG CONJUGATES TO TREAT HUMORAL IMMUNO-SUPPRESSED CANCERS

On February 4, 2020 Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Levena Biopharma, a company specialized in developing antibody drug conjugates (ADCs), reported the expanded collaboration to develop ADCs targeting humoral immuno-suppressed cancers (Press release, Navrogen, FEB 4, 2020, View Source [SID1234553828]). ADCs developed under this collaboration combine Levena’s linker and cytotoxic payload chemistry expertise along with Navrogen’s cancer-targeting antibodies discovered using its proprietary Humoral Immuno Oncology (HIO) platform technologies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Navrogen’s antibodies are able to specifically target and combat HIO-suppressed cancers that produce factors that dampen antibody-mediated immune-effector activity as well as decrease ADC internalization and subsequent release of their cytotoxic payloads which is required for killing. This collaboration will also include the use of Levena’s process development and GMP capabilities.

"Our collaboration with the exceptional scientists at Levena has enabled us to create a number of ADCs to specifically treat HIO-suppressed cancers," stated Luigi Grasso, Ph.D., Chief Scientific Officer at Navrogen. "The expansion of this collaboration will enable us to proceed with their advancement towards clinical trials."

Tong Zhu, Ph.D., Executive Director, Chemistry at Levena commented, "we have employed several of our technologies with the Navrogen team over the past year to identify HIO-refractory ADC formats. We look forward to continue supporting their development plans that can benefit from our expertise and technologies."

To Honor World Cancer Day, The WISDOM Study Seeks Support from Women to Modernize Breast Cancer Screening Guidelines

On February 4, 2020 Life Image reported that the WISDOM study, a groundbreaking effort to determine the optimal guidelines for breast cancer screening, is seeking qualifying women across the country that wish to participate in improving breast cancer screening and prevention (Press release, Life Image, FEB 4, 2020, View Source [SID1234553844]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The recent nation-wide expansion of WISDOM offers all women regardless of where they live, where they receive health care, or health insurance type the opportunity to participate in groundbreaking research and receive screening recommendations. The study seeks to enroll 100,000 women of all backgrounds to participate in an online study, and compares two different approaches to breast cancer screening: annual mammography versus a personalized approach based on risk. The results of the study aim to optimize breast cancer screening and improve treatment for millions of women and future generations of women.

Participation in the WISDOM study demonstrates personal commitment and support of World Cancer Day’s "I Am and I Will" campaign, an empowering movement uniting the world to fight against cancer through awareness and education.

The study will follow volunteers over time to determine whether a personalized risk-based approach to breast cancer screening can improve prevention and clinical outcomes for women when compared to the current, one-size-fits-all approach using standard annual mammograms.

Participation in the WISDOM study is free, and open to all women ages 40-74 who HAVE NOT been diagnosed with breast cancer. Participants may opt to be assigned at random to one of the study groups, or choose to be assigned to one of two study groups with different screening protocols:

Annual mammogram screenings – the current gold standard of care.
Personalized screening schedule based on factors including family history, genetics, lifestyle, and breast density.
Patients who are identified as being at high risk will be offered educational support from a genetic counselor, breast health specialist, and guidance for cancer risk reduction and prevention.

Over the course of the study, doctors will compare the two groups and determine if a personalized screening protocol can improve breast health outcomes for all women.

"We are proud to honor World Cancer Day and partner with the WISDOM study to help gather scientific evidence to make breast cancer screening safer and more effective, while empowering women with digital ownership of their own health records," said Matthew A. Michela, CEO of Life Image. "We encourage women in northern New Jersey and beyond to participate. It costs nothing and participation is simple, women are given the tools they need to support this research online throughout the duration of the study."

Participants in New Jersey can have their screenings done at Summit Medical Group, the first health care provider in New Jersey to participate in the study. By supporting the development of better screening guidelines, Summit Medical Group will assist in the creation of better tools to help women avoid unnecessary tests and procedures and lower the total cost of care. More information can be found at View Source

Life Image is the world’s largest medical exchange network specializing in diagnostic images. It is supporting the WISDOM study by offering participants Mammosphere, an electronic personal health app that enables women to securely request, store, and share their breast health history (including mammogram images) with the study or their healthcare providers.

Enrollment is simple and participation is fully online. To learn more about the WISDOM study or sign up, please visit www.wisdomstudy.org.

About The WISDOM Study
WISDOM is a five-year longitudinal study that compares two different approaches to breast cancer screening – annual mammography vs. a personalized, risk-based approach. The goal of the study is to determine whether personalized screening is more effective than annual screening. The personalized screening approach will take multiple risk factors into consideration, including genetic markers, to determine the most effective screening frequency and modality for an individual. Over time, we can learn which risk factors are most important and continue to improve our screening recommendations accordingly

Haemonetics 3rd Quarter Fiscal 2020 Earnings Release Available on Investor Relations Website

On February 4, 2020 Haemonetics Corporation (NYSE: HAE) reported that financial results for its third quarter fiscal 2020, which ended Dec. 28, 2019, are available on its Investor Relations website (Press release, Haemonetics, FEB 4, 2020, View Source [SID1234553860]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, the Company is also posting the earnings release and results tables that will be referenced on its webcast.

Direct link to Earnings Release 3Q and YTD FY 20:

View Source

Direct link to Results Tables 3Q and YTD FY 20 for reference on webcast conference call:

View Source

The Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8 a.m. EST Feb. 4, 2020. The call can be accessed with the following information:

U.S. / Canada toll free (877) 848-8880; International (716) 335-9512
Conference ID required for access: 1906607
A live webcast of the call can be accessed on Haemonetics’ Investor Relations website.
Direct link to conference call webcast: View Source